Pacira BioSciences (PCRX) Set to Post Quarterly Earnings on Thursday

Key Points

• Pacira BioSciences is scheduled to report Q3 2026 results after market close on November 5. Analysts expect earnings of $0.732 per share on revenue of approximately $182.87 million.
• The company exceeded expectations in its previous quarter, reporting $0.73 EPS versus the $0.65 consensus estimate and $192.40 million in revenue, up 6.2% year over year.
• Analyst sentiment remains cautious, with an average “Hold” rating and a $33.33 price target, while recent insider sales included transactions by a senior vice president and an insider under pre-arranged trading plans.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) is expected to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of $0.7320 per share and revenue of $182.87 million for the quarter. Interested persons can find conference call details on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.08. The business had revenue of $192.40 million for the quarter, compared to analyst estimates of $191.06 million. Pacira BioSciences had a net margin of 1.96% and a return on equity of 9.68%. The company's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.74 earnings per share. On average, analysts expect Pacira BioSciences to post $1.86 EPS for the current fiscal year and $2.37 EPS for the next fiscal year.

Pacira BioSciences Stock Down 0.0%

PCRX stock opened at $36.39 on Thursday. The company has a current ratio of 5.04, a quick ratio of 3.94 and a debt-to-equity ratio of 0.54. The firm has a 50-day moving average of $28.57 and a two-hundred day moving average of $24.68. Pacira BioSciences has a 12 month low of $18.80 and a 12 month high of $36.67. The company has a market cap of $1.45 billion, a price-to-earnings ratio of 103.97 and a beta of 0.25.

Insider Activity

In other Pacira BioSciences news, insider Jonathan Slonin sold 3,040 shares of the business's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $23.23, for a total value of $70,619.20. Following the transaction, the insider directly owned 216,384 shares in the company, valued at $5,026,600.32. The trade was a 1.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Lauren Riker sold 6,000 shares of the stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $36.32, for a total transaction of $217,920.00. Following the completion of the sale, the senior vice president directly owned 62,284 shares of the company's stock, valued at approximately $2,262,154.88. This trade represents a 8.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

PCRX has been the subject of a number of analyst reports. Zacks Research lowered Pacira BioSciences from a "hold" rating to a "strong sell" rating in a research report on Monday, October 5th. Needham & Company LLC downgraded Pacira BioSciences from a "buy" rating to a "hold" rating in a research report on Thursday, October 8th. Royal Bank Of Canada lifted their price objective on Pacira BioSciences from $25.00 to $36.50 and gave the stock a "sector perform" rating in a research report on Friday, October 9th. Weiss Ratings raised Pacira BioSciences from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, October 8th. Finally, Oppenheimer initiated coverage on Pacira BioSciences in a report on Wednesday, September 23rd. They issued an "outperform" rating and a $32.00 target price for the company. One analyst has rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Pacira BioSciences currently has an average rating of "Hold" and an average target price of $33.33.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management and regenerative health solutions. The company's products are designed to address acute postsurgical pain and osteoarthritis-related pain while supporting efforts to reduce reliance on opioid medications.

Pacira's lead product is EXPAREL, an extended-release formulation of bupivacaine administered by injection for postsurgical pain management. The company also markets ZILRETTA, an extended-release corticosteroid injection indicated for osteoarthritis knee pain, and iovera°, a cryoanalgesia system that uses controlled cooling to temporarily block peripheral nerves and relieve pain.

Formerly known as Pacira Pharmaceuticals, the company adopted the Pacira BioSciences name to reflect its broader focus on innovative pain and regenerative-health therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.